South San Francisco, United States
Frontier Medicines is a biopharmaceutical innovator transforming the landscape of drug discovery. Its mission to "drug the undruggable" is revolutionizing patient care by targeting disease-causing proteins once deemed untreatable. Founded in 2018, this precision medicine company operates from both South San Francisco, CA and Boston, MA.
Frontier Medicines has developed a cutting-edge discovery and development platform, leveraging breakthroughs in chemoproteomics, covalent drug discovery, and machine learning. Their pipeline's centerpiece is a revolutionary program targeting both forms of KRAS G12C, a major cancer driver previously thought undruggable.
This approach has attracted significant investor interest. Notably, Frontier recently secured a $20.00M Series C investment on 01 June 2024, led by prominent investors ArrowMark Partners and Deep Track Capital. Focusing on the sectors of Biopharma, Biotechnology, Life Sciences, and Pharmaceutical, the company is well-positioned to make a profound impact on the life sciences industry.
Sibylla Biotech
